- Home
- MAMK vs OTLK Comparison
MAMK vs OTLK Comparison
Compare MAMK & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMK
- OTLK
- Stock Information
- Founded
- MAMK 2007
- OTLK 2010
- Country
- MAMK China
- OTLK United States
- Employees
- MAMK N/A
- OTLK N/A
- Industry
- MAMK Apparel
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAMK Consumer Discretionary
- OTLK Health Care
- Exchange
- MAMK Nasdaq
- OTLK Nasdaq
- Market Cap
- MAMK 43.2M
- OTLK 42.8M
- IPO Year
- MAMK 2025
- OTLK 2016
- Fundamental
- Price
- MAMK N/A
- OTLK $1.26
- Analyst Decision
- MAMK
- OTLK Buy
- Analyst Count
- MAMK 0
- OTLK 5
- Target Price
- MAMK N/A
- OTLK $5.25
- AVG Volume (30 Days)
- MAMK 103.4K
- OTLK 2.7M
- Earning Date
- MAMK 01-01-0001
- OTLK 08-14-2025
- Dividend Yield
- MAMK N/A
- OTLK N/A
- EPS Growth
- MAMK N/A
- OTLK N/A
- EPS
- MAMK 0.12
- OTLK N/A
- Revenue
- MAMK $21,434,100.00
- OTLK $1,505,322.00
- Revenue This Year
- MAMK N/A
- OTLK N/A
- Revenue Next Year
- MAMK N/A
- OTLK $343.94
- P/E Ratio
- MAMK $23.16
- OTLK N/A
- Revenue Growth
- MAMK N/A
- OTLK N/A
- 52 Week Low
- MAMK $1.87
- OTLK $0.79
- 52 Week High
- MAMK $4.00
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- MAMK N/A
- OTLK 50.51
- Support Level
- MAMK N/A
- OTLK $1.04
- Resistance Level
- MAMK N/A
- OTLK $1.13
- Average True Range (ATR)
- MAMK 0.00
- OTLK 0.06
- MACD
- MAMK 0.00
- OTLK 0.06
- Stochastic Oscillator
- MAMK 0.00
- OTLK 96.32
About MAMK MaxsMaking Inc. Class A Ordinary Shares
MaxsMaking Inc is a manufacturer of consumer goods with a focus on technology and innovation. It is serving small and medium-sized enterprises and individual e-commerce sellers with their needs for small batch products, It currently use cotton cloth, nylon cloth, polyester, recycled polyethylene terephthalate (rPET) and other materials to produce backpacks, shopping bags, aprons, tablecloths and other consumer goods. It serve enterprises, schools, government agencies, non-profit organizations, e-commerce sellers and various groups and organizations to meet their needs for small-batch products.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.